Ascendis åbner nyt selskab for at nå Kina

Sammen med kapitalfonden Vivo Capital har Ascendis Pharma stiftet et nyt selskab i Kina, som skal hjælpe virksomheden med at slå igennem på de kinesiske marked med Ascendis' tre hovedprodukter.
Photo: Andy Wong/AP
Photo: Andy Wong/AP

Med 40 mio. dollar (cirka 263 mio. kr.) i ryggen fra et investorsyndikat ledet af Vivo Capital har Ascendis Pharma smedet et nyt selskab i Kina, Visen Pharmaceuticals.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Further reading